{"entity":{"id":"gemcitabine-nab-paclitaxel","kind":"drug","name":"Gemcitabine + nab-paclitaxel","aka":[],"tldr":"Gemcitabine plus nab-paclitaxel is the gentler of the two standard chemotherapy backbones for pancreatic cancer, and the base on which most new drugs are being tested.","summary":"MPACT (2013): OS 8.5 vs 6.7 months versus gemcitabine alone. Preferred for less fit patients; the control or backbone arm in PANOVA-3 (TTFields), zoldonrasib first-line combinations, and CLDN18.2 and other add-on trials. Gemcitabine monotherapy (1997) was the standard for 14 years before FOLFIRINOX.","status":"standard-of-care","asOf":"2026-09-06","wikipedia":"https://en.wikipedia.org/wiki/Gemcitabine","links":[{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Gemcitabine"},{"label":"NICE TA476 (6 September 2017)","url":"https://www.nice.org.uk/guidance/ta476"}],"tags":[],"related":[],"cancers":["pancreatic","locally-advanced-pdac","metastatic-pdac"],"sections":[],"technologies":["cytotoxic-chemotherapy"],"targets":[],"drugs":["paclitaxel"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["panova-3","nct05257993","nct04589234","mpact","apact","canstem111p","halo-301","resolve","neolap","neonax","swog-s1505","scalop-2","starpac2","primus-001"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Pancreatic cancer, UK status: NICE TA476 (6 September 2017) recommends the combination for untreated metastatic disease only if other combination chemotherapies are unsuitable and the person would otherwise have gemcitabine alone; NICE NG85 1.9.5 repeats this. Adjuvant use missed its primary endpoint in APACT and is not recommended by NICE or NCCN. It is the control arm of PANOVA-3, NAPOLI 3, CanStem111P (median 11.7 months), HALO-301, RESOLVE and RASolute 303."],"brand":"Gemzar + Abraxane","modality":"Cytotoxic regimen","mechanism":"Nucleoside analogue (gemcitabine) plus albumin-bound taxane that may deplete stroma and increase gemcitabine delivery.","approvals":[{"region":"US","year":2013,"indication":"First-line metastatic pancreatic adenocarcinoma (nab-paclitaxel label)"}],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/gemcitabine-nab-paclitaxel/","neighbours":{"cancer":[{"id":"pancreatic-adenosquamous-carcinoma","kind":"cancer","name":"Adenosquamous carcinoma of the pancreas","route":"/cancers/pancreatic-adenosquamous-carcinoma/"},{"id":"ampullary","kind":"cancer","name":"Ampullary cancer (ampulla of Vater)","route":"/cancers/ampullary/"},{"id":"borderline-resectable-pdac","kind":"cancer","name":"Borderline resectable pancreatic ductal adenocarcinoma","route":"/cancers/borderline-resectable-pdac/"},{"id":"brca-palb2-pdac","kind":"cancer","name":"BRCA or PALB2-mutant pancreatic ductal adenocarcinoma","route":"/cancers/brca-palb2-pdac/"},{"id":"pancreatic-colloid-carcinoma","kind":"cancer","name":"Colloid (mucinous non-cystic) carcinoma of the pancreas","route":"/cancers/pancreatic-colloid-carcinoma/"},{"id":"ipmn-associated-carcinoma","kind":"cancer","name":"Invasive carcinoma arising in an intraductal papillary mucinous neoplasm (IPMN-associated carcinoma)","route":"/cancers/ipmn-associated-carcinoma/"},{"id":"kras-g12c-pdac","kind":"cancer","name":"KRAS G12C-mutant pancreatic ductal adenocarcinoma","route":"/cancers/kras-g12c-pdac/"},{"id":"kras-wild-type-pdac","kind":"cancer","name":"KRAS wild-type pancreatic ductal adenocarcinoma","route":"/cancers/kras-wild-type-pdac/"},{"id":"locally-advanced-pdac","kind":"cancer","name":"Locally advanced unresectable pancreatic ductal adenocarcinoma","route":"/cancers/locally-advanced-pdac/"},{"id":"metastatic-pdac","kind":"cancer","name":"Metastatic pancreatic ductal adenocarcinoma","route":"/cancers/metastatic-pdac/"},{"id":"msi-high-pdac","kind":"cancer","name":"Mismatch repair deficient (MSI-high) pancreatic ductal adenocarcinoma","route":"/cancers/msi-high-pdac/"},{"id":"mcn-associated-carcinoma","kind":"cancer","name":"Mucinous cystic neoplasm of the pancreas with associated invasive carcinoma (MCN-associated carcinoma)","route":"/cancers/mcn-associated-carcinoma/"},{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"},{"id":"resectable-pdac","kind":"cancer","name":"Resectable pancreatic ductal adenocarcinoma","route":"/cancers/resectable-pdac/"},{"id":"pancreatic-undifferentiated-carcinoma-ogc","kind":"cancer","name":"Undifferentiated carcinoma of the pancreas with osteoclast-like giant cells","route":"/cancers/pancreatic-undifferentiated-carcinoma-ogc/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"}],"drug":[{"id":"paclitaxel","kind":"drug","name":"Paclitaxel / nab-paclitaxel","route":"/drugs/paclitaxel/"}],"trial":[{"id":"nct07043270","kind":"trial","name":"24BRO681 : Alternating Gnp and mFOLFIRINOX for BR-PDAC","route":"/trials/nct07043270/"},{"id":"nct07336953","kind":"trial","name":"A Phase III, Randomized, Clinical Trial of GnP Combined With SBRT and Serplulimab Versus GnP as First-Line Treatment for Patients With Recurrent or Metastatic P","route":"/trials/nct07336953/"},{"id":"nct05969171","kind":"trial","name":"A Single-center, Prospective, Two Cohort Study of Surufatinib Combined With AG or AG in the First-line Treatment of Locally Advanced or Metastatic Pancreatic Ca","route":"/trials/nct05969171/"},{"id":"actuate-1801","kind":"trial","name":"Actuate 1801 Part 3B (elraglusib)","route":"/trials/actuate-1801/"},{"id":"nct06938503","kind":"trial","name":"AG Plus Nimotuzumab Sequential Irreversible Electroporation Ablation for Locally Advanced Pancreatic Cancer","route":"/trials/nct06938503/"},{"id":"nct06621095","kind":"trial","name":"Anlotinib Plus Benmelstobart and AG in First-line Treatment of Advanced Metastatic Pancreatic Cancer (ALTER-PA-001)","route":"/trials/nct06621095/"},{"id":"apact","kind":"trial","name":"APACT","route":"/trials/apact/"},{"id":"canstem111p","kind":"trial","name":"CanStem111P","route":"/trials/canstem111p/"},{"id":"nct07235930","kind":"trial","name":"Firstline Sequential AG and mFOLFOX Combined With Serplulimab and Bevacizumab Versus AG Chemotherapy Alone in Advanced Pancreatic Cancer","route":"/trials/nct07235930/"},{"id":"halo-301","kind":"trial","name":"HALO 109-301","route":"/trials/halo-301/"},{"id":"nct06770452","kind":"trial","name":"HRS-4642 With Nimotuzumab and Chemotherapy for First-line Treatment of Advanced Pancreatic Cancer Patients","route":"/trials/nct06770452/"},{"id":"lapis-trial","kind":"trial","name":"LAPIS","route":"/trials/lapis-trial/"},{"id":"nct07312422","kind":"trial","name":"LDRT Combined With Pucotenlimab and Standard Therapy for Advanced Pancreatic Cancer: A Single-Arm Study","route":"/trials/nct07312422/"},{"id":"mpact","kind":"trial","name":"MPACT","route":"/trials/mpact/"},{"id":"napoli-3","kind":"trial","name":"NAPOLI 3","route":"/trials/napoli-3/"},{"id":"nct05268692","kind":"trial","name":"Neoadjuvant Chemotherapy for Pancreatic Cancer Followed by GS and GnP","route":"/trials/nct05268692/"},{"id":"neolap","kind":"trial","name":"NEOLAP","route":"/trials/neolap/"},{"id":"neonax","kind":"trial","name":"NEONAX","route":"/trials/neonax/"},{"id":"nct07277452","kind":"trial","name":"Nimotuzumab Combined With Nab-paclitaxel/Gemcitabine in the Perioperative Treatment of High-risk Resectable/Borderline Resectable Pancreatic Cancer","route":"/trials/nct07277452/"},{"id":"panova-3","kind":"trial","name":"PANOVA-3","route":"/trials/panova-3/"},{"id":"primus-001","kind":"trial","name":"PRIMUS 001","route":"/trials/primus-001/"},{"id":"nct07110064","kind":"trial","name":"QL1706+Lenvatinib+AG Regimen as First-line Treatment for Advanced Metastatic Pancreatic Cancer","route":"/trials/nct07110064/"},{"id":"resolve","kind":"trial","name":"RESOLVE","route":"/trials/resolve/"},{"id":"nct04589234","kind":"trial","name":"Saltikva for Metastatic Pancreatic Cancer","route":"/trials/nct04589234/"},{"id":"nct07683221","kind":"trial","name":"SBRT Followed by Ipilimumab N01, Sintilimab, Nab-Paclitaxel and Gemcitabine for Locally Advanced Pancreatic Cancer","route":"/trials/nct07683221/"},{"id":"scalop-2","kind":"trial","name":"SCALOP-2","route":"/trials/scalop-2/"},{"id":"starpac2","kind":"trial","name":"STARPAC2","route":"/trials/starpac2/"},{"id":"nct05257993","kind":"trial","name":"Study to Assess the Safety, Tolerability of JPI-547 in Combination With Modified FOLFIRINOX or Gemcitabine-nab-paclitaxel in Patients With Locally Adv","route":"/trials/nct05257993/"},{"id":"nct07833241","kind":"trial","name":"Surufatinib in Combination With Iparomlimab and Tuvonralimab Injection and AG Chemotherapy for Neoadjuvant Therapy of HRPC or BRPC","route":"/trials/nct07833241/"},{"id":"nct05218889","kind":"trial","name":"Surufatinib Plus Camrelizumab and AS in First Line Treatment of Advanced Metastatic Pancreatic Cancer","route":"/trials/nct05218889/"},{"id":"nct07436741","kind":"trial","name":"Surufatinib Plus Gemcitabine and Nab-paclitaxel vs. Gemcitabine Plus Nab-paclitaxel in Neoadjuvant Therapy for High - Risk Resectable or Borderline Resectable P","route":"/trials/nct07436741/"},{"id":"swog-s1505","kind":"trial","name":"SWOG S1505","route":"/trials/swog-s1505/"},{"id":"trybeca-1","kind":"trial","name":"TRYbeCA-1","route":"/trials/trybeca-1/"}],"term":[{"id":"classical-vs-basal-like","kind":"term","name":"Classical versus basal-like (squamous) subtypes of pancreatic cancer, and GATA6","route":"/terms/classical-vs-basal-like/"},{"id":"chemotherapy-side-effects-pancreatic","kind":"term","name":"Living with FOLFIRINOX, NALIRIFOX and gemcitabine with nab-paclitaxel","route":"/terms/chemotherapy-side-effects-pancreatic/"},{"id":"pancreatic-cancer-uk-drug-access","kind":"term","name":"Pancreatic cancer drugs in England: NICE appraisals and the Cancer Drugs Fund (September 2026)","route":"/terms/pancreatic-cancer-uk-drug-access/"}],"paper":[{"id":"paper-asco-metastatic-pancreatic-cancer-guideline-update-jco-2020","kind":"paper","name":"Metastatic Pancreatic Cancer: ASCO Guideline Update","route":"/key-papers/paper-asco-metastatic-pancreatic-cancer-guideline-update-jco-2020/"},{"id":"paper-mpact-nab-paclitaxel-gemcitabine-nejm-2013","kind":"paper","name":"MPACT (Von Hoff 2013): nab-paclitaxel plus gemcitabine for metastatic pancreatic cancer","route":"/key-papers/paper-mpact-nab-paclitaxel-gemcitabine-nejm-2013/"},{"id":"paper-halo-301-pegvorhyaluronidase-jco-2020","kind":"paper","name":"Randomized Phase III Trial of Pegvorhyaluronidase Alfa With Nab-Paclitaxel Plus Gemcitabine for Patients With Hyaluronan-High Metastatic Pancreatic Adenocarcinoma","route":"/key-papers/paper-halo-301-pegvorhyaluronidase-jco-2020/"},{"id":"paper-panova-3-ttfields-locally-advanced-pancreatic-jco-2025","kind":"paper","name":"Tumor Treating Fields With Gemcitabine and Nab-Paclitaxel for Locally Advanced Pancreatic Adenocarcinoma: Randomized, Open-Label, Pivotal Phase III PANOVA-3 Study","route":"/key-papers/paper-panova-3-ttfields-locally-advanced-pancreatic-jco-2025/"}],"roadmap":[{"id":"pancreatic-roadmap","kind":"roadmap","name":"Pancreatic cancer roadmap: from Whipple's operation to gemcitabine, FOLFIRINOX, adjuvant chemotherapy, PARP inhibition, KRAS inhibition, vaccines and the surveillance question","route":"/roadmaps/pancreatic-roadmap/"}],"idea":[{"id":"idea-pdac-cachexia-trials-embedded-in-chemotherapy-trials","kind":"idea","name":"Embed cachexia treatment in chemotherapy trials: weight, muscle and treatment delivery as co-primary endpoints","route":"/ideas/idea-pdac-cachexia-trials-embedded-in-chemotherapy-trials/"},{"id":"idea-pdac-ras-inhibitor-combinations-and-sequencing","kind":"idea","name":"RAS inhibitor combinations and sequence: pan-RAS plus G12D-selective, plus chemotherapy, and what to give after progression","route":"/ideas/idea-pdac-ras-inhibitor-combinations-and-sequencing/"}]}}